产品名称

英文名称：ENMD-2076 L-(+)-Tartaric acid

同义词

EX-A235A、ENMD-2076 Tartrate、AKOS027295002、(2S,3S)-2,3-Dihydroxybutanedioic acid--6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine (1/1)、SCHEMBL23535026、AS-76232、DTXSID90735339、HY-10987、1291074-87-7、ENMD-2076、ENMD-2076 酒石酸盐

产品性质

CAS编号：1291074-87-7

分子式：C25H31N7O6

分子量：525.56

PubChem编号：66576993

别名：ENMD-2076 酒石酸盐

英文别名：EX-A235A|ENMD-2076 Tartrate|AKOS027295002|(2S,3S)-2,3-Dihydroxybutanedioic acid--6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine (1/1)|SCHEMBL23535026|AS-76232|DTXSID90735339|HY-10987|1291074-87-7|ENMD-2076

规格或纯度：≥99%

英文名称：ENMD-2076 L-(+)-Tartaric acid

生化机理：ENMD-2076 is a antiangiogenic and Aurora kinase inhibitor with IC50 of 3, 13, 350, 23, 40, 93 and 120 nM for Flt-3, AurA, AurB, Src, KDR/VEGFR2 and FGFR1.

储存温度：-20°C储存

运输条件：超低温冰袋运输

产品介绍：ENMD-2076 L-(+)-Tartaric acid 是ENMD-2076的酒石酸，选择性作用于Aurora A和VEGFR(Flt3)，IC50分别为14 nM和1.86 nM，作用于Aurora A比作用于Aurora B选择性高25倍，对VEGFR2/KDR和VEGFR3， FGFR1和FGFR2和PDGFRα作用效果稍弱。Phase 2。ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

IUPAC Name：(2S,3S)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine

INCHI：InChI=1S/C21H25N7.C4H6O6/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17;5-1(3(7)8)2(6)4(9)10/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26);1-2,5-6H,(H,7,8)(H,9,10)/b9-8+;/t;1-,2-/m.0/s1

InChi Key：KGWWHPZQLVVAPT-PCWHHUEVSA-N

Canonical SMILES：CC1=CC(=NN1)NC2=CC(=NC(=N2)C=CC3=CC=CC=C3)N4CCN(CC4)C.C(C(C(=O)O)O)(C(=O)O)O

Isomeric SMILES：CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O

PubChem CID：66576993

溶解性：DMSO

敏感性：对湿度敏感

产品包装